CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Paricalcitol +1 moredrug
Likely dose
Paricalcitol 1 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01003275
NCT01003275Phase 2Completed
CompareCT.gov

Effects of Oral Paricalcitol on Glucose Tolerance, Immune Cell Function, and Oxidative Stress in Stage 3-4 Chronic Kidney Disease

University of Washington·interventional·Posted Oct 28, 2009·Updated Apr 28, 2014

In Brief

A Phase 2 clinical trial evaluating Paricalcitol and Placebo for Chronic Kidney Disease. Completed, enrolled 22 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if treatment with paricalcitol, an active form of vitamin D, has beneficial effects on metabolic abnormalities in people with stage 3-4 Chronic Kidney Disease (CKD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsAbbott

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 28, 2009
Enrollment StartOct 1, 2009
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 16.7 years ago

Interventions

Paricalcitoldrug

Two 1 mcg soft gels by mouth daily for 8 weeks

Placebodrug

Two soft gels by mouth daily for 8 weeks